These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 27083881

  • 1. Update on the pharmacotherapy of cerebellar and central vestibular disorders.
    Kalla R, Teufel J, Feil K, Muth C, Strupp M.
    J Neurol; 2016 Apr; 263 Suppl 1():S24-9. PubMed ID: 27083881
    [Abstract] [Full Text] [Related]

  • 2. Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders.
    Kalla R, Strupp M.
    Curr Neuropharmacol; 2019 Apr; 17(1):7-13. PubMed ID: 30182858
    [Abstract] [Full Text] [Related]

  • 3. Aminopyridines for the treatment of cerebellar and ocular motor disorders.
    Strupp M, Kalla R, Glasauer S, Wagner J, Hüfner K, Jahn K, Brandt T.
    Prog Brain Res; 2008 Apr; 171():535-41. PubMed ID: 18718350
    [Abstract] [Full Text] [Related]

  • 4. Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.
    Feil K, Bremova T, Muth C, Schniepp R, Teufel J, Strupp M.
    Cerebellum; 2016 Feb; 15(1):38-42. PubMed ID: 26519380
    [Abstract] [Full Text] [Related]

  • 5. [Pharmacotherapy of Vestibular Disorders, Nystagmus and Cerebellar Disorders].
    Feil K, Böttcher N, Kremmyda O, Muth C, Teufel J, Zwergal A, Brandt T, Strupp M.
    Fortschr Neurol Psychiatr; 2015 Sep; 83(9):490-8. PubMed ID: 26421856
    [Abstract] [Full Text] [Related]

  • 6. Pharmacotherapy of vestibular and cerebellar disorders and downbeat nystagmus: translational and back-translational research.
    Strupp M, Zwergal A, Feil K, Bremova T, Brandt T.
    Ann N Y Acad Sci; 2015 Apr; 1343():27-36. PubMed ID: 25903394
    [Abstract] [Full Text] [Related]

  • 7. [Pharmacotherapy of Vestibular Disorders, Nystagmus and Cerebellar Disorders].
    Feil K, Böttcher N, Kremmyda O, Muth C, Teufel J, Zwergal A, Brandt T, Strupp M.
    Laryngorhinootologie; 2018 Jan; 97(1):14-23. PubMed ID: 29301160
    [Abstract] [Full Text] [Related]

  • 8. Pharmacotherapy of vestibular disorders and nystagmus.
    Strupp M, Kremmyda O, Brandt T.
    Semin Neurol; 2013 Jul; 33(3):286-96. PubMed ID: 24057832
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological advances in the treatment of neuro-otological and eye movement disorders.
    Strupp M, Brandt T.
    Curr Opin Neurol; 2006 Feb; 19(1):33-40. PubMed ID: 16415675
    [Abstract] [Full Text] [Related]

  • 10. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.
    Kalla R, Glasauer S, Büttner U, Brandt T, Strupp M.
    Brain; 2007 Sep; 130(Pt 9):2441-51. PubMed ID: 17664175
    [Abstract] [Full Text] [Related]

  • 11. Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia.
    Shaikh AG, Marti S, Tarnutzer AA, Palla A, Crawford TO, Zee DS, Straumann D.
    J Neurol; 2013 Nov; 260(11):2728-35. PubMed ID: 23884713
    [Abstract] [Full Text] [Related]

  • 12. The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus.
    Glasauer S, Rössert C, Strupp M.
    Ann N Y Acad Sci; 2011 Sep; 1233():162-7. PubMed ID: 21950989
    [Abstract] [Full Text] [Related]

  • 13. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
    Strupp M, Schüler O, Krafczyk S, Jahn K, Schautzer F, Büttner U, Brandt T.
    Neurology; 2003 Jul 22; 61(2):165-70. PubMed ID: 12874393
    [Abstract] [Full Text] [Related]

  • 14. Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus.
    Strupp M, Thurtell MJ, Shaikh AG, Brandt T, Zee DS, Leigh RJ.
    J Neurol; 2011 Jul 22; 258(7):1207-22. PubMed ID: 21461686
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.
    Kalla R, Spiegel R, Claassen J, Bardins S, Hahn A, Schneider E, Rettinger N, Glasauer S, Brandt T, Strupp M.
    J Neuroophthalmol; 2011 Dec 22; 31(4):320-5. PubMed ID: 21734596
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.
    Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T.
    Neurology; 2004 May 11; 62(9):1623-5. PubMed ID: 15136697
    [Abstract] [Full Text] [Related]

  • 19. [Pharmacotherapy of central oculomotor disorders].
    Kalla R, Spiegel R, Wagner J, Rettinger N, Jahn K, Strupp M.
    Nervenarzt; 2008 Dec 11; 79(12):1377-8, 1380-2, 1384-5. PubMed ID: 18633586
    [Abstract] [Full Text] [Related]

  • 20. 4-Aminopyridine suppresses positional nystagmus caused by cerebellar vermis lesion.
    Kremmyda O, Zwergal A, la Fougère C, Brandt T, Jahn K, Strupp M.
    J Neurol; 2013 Jan 11; 260(1):321-3. PubMed ID: 23180177
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.